Supplementary Materialsgfz062_Supplementary_Material

Supplementary Materialsgfz062_Supplementary_Material. difference 0.23% Exatecan Mesylate (95% CI 0.13C0.34)]. There is no association between NSAID make use of and all-cause mortality. A prediction model included six predictors of AKI or hyperkalemia: old age, man gender, lower baseline approximated glomerular filtration price, higher baseline serum potassium, angiotensin-converting enzyme angiotensin or inhibitor receptor blocker use or diuretic use. This model acquired moderate discrimination [C-statistic 0.72 (95% CI 0.70C0.74)] and great calibration. Conclusions In old adults, brand-new NSAID use weighed against nonuse was connected with an increased 30-day threat of AKI and hyperkalemia however, not all-cause mortality. Prescription NSAID make use of among many old adults may be secure, but providers should use assess and caution individual risk. that are often ascertained used and were connected with an increased threat of AKI or hyperkalemia in the books: older age Exatecan Mesylate group [35C37], feminine sex [36, 38], lower baseline eGFR [35, 36, 38], higher baseline serum potassium focus [39], higher NSAID dosage [40, 41], ACEi/ARB make use of [35, make use of and 42] of loop, potassium-sparing or thiazide-type diuretics [35, 37, 42]. We held continuous variables assumed and continuous that their romantic relationship with the results was linear. We performed stepwise multivariable logistic regression utilizing a P(%)36?016 (58.8)84?355 (53.9)1026?654 (57.8)26?552 (57.6)0?Rural status, (%)a3489 (5.7)8431 (5.4)12298 (5.0)2334 (5.1)0?Income quintile, (%)b??1 (lowest)11?523 (18.8)26?116 (16.7)58337 (18.1)8234 (17.9)1??212?365 (20.2)29?469 (18.8)49215 (20.0)9055 (19.6)1??312?823 (20.9)31?049 (19.8)39510 (20.6)9457 (20.5)0??412?653 (20.7)33?721 (21.5)29622 (20.9)9680 (21.0)0??5 (highest)11?855 (19.4)36?234 (23.1)99423 (20.4)9681 (21.0)1Index prescription details?Index NSAID is a COX2 inhibitor, (%)30?741 (50.2)23?208 (50.3)?Percentage of optimum daily medication dosage, mean (SD)61.9 (28.3)61.5 (28.2)Prescribing physician characteristics?Age (years), mean (SD)55.6 (11.3)55.8 (11.3)??Missing, (%)3256 (5.3)2395 (5.2)?Feminine sex, (%)15?972 (26.1)12?019 (26.1)??Missing, (%)2620 (4.3)1862 (4.0)?Rural status, (%)2719 (4.4)1778 (3.9)??Missing, (%)2574 (4.2)1827 (4.0)?Medical specialty, (%)??Principal treatment52?772 (86.2)40?040 (86.8)??Nephrologist54 (0.1)38 (0.1)??Cardiologist127 (0.2)107 (0.2)??Other5694 (9.3)4097 (8.9)??Missing2572 (4.2)1825 (4.0)Healthcare visits in prior calendar year, (%)?Charlson comorbidity rating??0 or zero hospitalization46?909 (76.6)104?469 (66.7)2235?055 (76.0)34?918 (75.7)1??16668 (10.9)19?989 (12.8)65017 (10.9)5089 (11.0)0??24426 (7.2)15?417 Exatecan Mesylate (9.8)93442 (7.5)3493 (7.6)0??33216 (5.3)16?714 (10.7)202593 (5.6)2607 (5.7)0?John Hopkins ADG score, mean (SD)12.4 (4.0)11.6 PBT (4.2)1812.1 (4.0)12.1 (4.0)1?Ischemic heart disease15?950 (26.1)49?501 (31.6)1212?150 (26.4)12?265 (26.6)0?Congestive heart failure4105 (6.7)21?268 (13.6)233178 (6.9)3269 (7.1)1?Ventricular arrhythmia91 (0.1)791 (0.5)771 (0.2)76 (0.2)0?Myocardial infarction2119 (3.5)8828 (5.6)101634 (3.5)1686 (3.7)1?Peripheral vascular disease2320 (3.8)7572 (4.8)51752 (3.8)1736 (3.8)0?Atrial fibrillation1548 (2.5)12?489 (8.0)251277 (2.8)1407 (3.1)2?Coronary artery bypass graft570 (0.9)2?301 (1.5)6450 (1.0)479 (1.0)0?Percutaneous coronary intervention1360 (2.2)4957 (3.2)61091 (2.4)1093 (2.4)0?Diabetes22?177 (36.2)57?397 (36.7)116?653 (36.1)16?610 (36.0)0?Hypertension46?410 (75.8)116?542 (74.4)334?526 (74.9)34?391 (74.6)1?Chronic liver disease642 (1.0)2455 (1.6)5509 (1.1)519 (1.1)0?Chronic lung disease14?709 (24.0)34?723 (22.2)410?473 (22.7)10?403 (22.6)0?Malignancy7407 (12.1)21?501 (13.7)55669 (12.3)5657 (12.3)0?Osteoporosis10?193 (16.7)23?428 (15.0)57570 (16.4)7519 (16.3)0?Joint disease34?669 (56.6)44?363 (28.3)6023?064 (50.0)22?681 (49.2)2?Joint disorder7378 (12.1)9779 (6.2)214706 (10.2)4572 (9.9)1?Bursitis18?345 (30.0)23?268 (14.9)3711?902 (25.8)11?626 (25.2)1?Fibromyalgia4417 (7.2)5305 (3.4)172686 (5.8)2514 (5.5)1?Fracture7630 (12.5)20?413 (13.0)15634 (12.2)5558 (12.1)0?Hip fracture531 (0.9)3297 (2.1)10436 (0.9)454 (1.0)1?Back pain30?486 (49.8)41?164 (26.3)5020?383 (44.2)20?051 (43.5)1?Back surgery treatment790 (1.3)836 (0.5)8454 (1.0)428 (0.9)1?Knee surgery treatment3829 (6.3)3755 (2.4)192221 (4.8)2130 (4.6)1?Hip surgery1612 (2.6)2604 (1.7)61091 (2.4)1091 (2.4)0?Cerebrovascular disease4783 (7.8)20?211 (12.9)173765 (8.2)3778 (8.2)0?Dementia3729 (6.1)24?123 (15.4)303142 (6.8)3106 (6.7)0?Migraine2649 (4.3)4491 (2.9)81801 (3.9)1804 (3.9)0?Gout4985 (8.1)4581 (2.9)232804 (6.1)2426 (5.3)3?Rheumatoid arthritis3994 (6.5)4517 (2.9)172436 (5.3)2320 (5.0)1?Osteoarthritis7031 (11.5)7861 (5.0)244?245 (9.2)4163 (9.0)1?Sciatica21?449 (35.0)26?131 (16.7)4313?872 (30.1)13?479 (29.2)2?Pain32?285 (52.7)54?717 (34.9)3622?548 (48.9)22?434 (48.7)0?Schizophrenia704 (1.1)3766 (2.4)10576 (1.2)580 (1.3)1?Depression5161 (8.4)13?267 (8.5)03729 (8.1)3766 (8.2)0Health care and attention procedures in previous 12 months, (%)?Carotid ultrasound2812 (4.6)8492 (5.4)42179 (4.7)2230 (4.8)0?Coronary angiogram1005 (1.6)3557 (2.3)5785 (1.7)797 (1.7)0?Coronary revascularization415 (0.7)1731 (1.1)4344 (0.7)359 (0.8)1?Echocardiogram12?466 (20.4)37?234 (23.8)89526 (20.7)9649 (20.9)0?Holter test4684 (7.7)14?820 (9.5)63616 (7.8)3675 (8.0)1?Stress test8472 (13.8)19?822 (12.7)36223 (13.5)6213 (13.5)0?Cardiac catheterization1032 (1.7)3?699 (2.4)5807 (1.8)819 (1.8)0?Back X-ray29?048 (47.4)44?677 (28.5)4019?685 (42.7)19?347 (42.0)1?At least one albumin:creatinine percentage test35?803 (58.5)79?468 (50.7)1626?481 (57.4)26?330 (57.1)1Laboratory checks in previous year?Time from baseline serum creatinine to index day (days), median (IQR)94 (33C192)88 (34C179)94 (32C193)95 (37C187)?Baseline serum creatinine value (mg/dL), mean (SD)0.9 (0.3)1.0 (0.4)270.9 (0.3)0.9 (0.3)0?Baseline eGFR value (mL/min/1.73 m2), mean (SD)73.0 Exatecan Mesylate (16.0)69.1 (18.6)2373.0 (16.0)73.0 (16.0)0?Baseline potassium value (mEq/L), mean (SD)4.4 (0.4)4.4 (0.4)24.4 (0.4)4.4 (0.4)0Prescriptions in prior 120 days, (%)?Aspirin1549 (2.5)2532 (1.6)61018 (2.2)959 (2.1)1?Tylenol2939 (4.8)2879 (1.8)171664 (3.6)1473 (3.2)2?Opiates12?499 (20.4)15?521 (9.9)307697 (16.7)7166 (15.5)3?ACEi15?898 (26.0)48?917 (31.2)1212?190 (26.4)12?190 (26.4)0?ARB16?618 (27.1)37?556 (24.0)712?139 (26.3)12?139 (26.3)0?Statin32?296 (52.8)84?994 (54.3)324?343 (52.8)24?269 (52.6)0?Diabetes drug13?159 (21.5)37?247 (23.8)510?097 (21.9)10?087 (21.9)0?Calcium channel blocker16?386 (26.8)45?357 (29.0)512?400 (26.9)12?244 (26.6)1?-blocker14?136 (23.1)48?987 (31.3)1910?921 (23.7)11?045 (24.0)1?Proton pump inhibitor24?196 (39.5)40?148 (25.6)3016?246 (35.2)15?737 (34.1)2?Thiazide diuretic8871 (14.5)22?768 (14.5)06461 (14.0)6466 (14.0)0?Loop diuretic3137 (5.1)16?247 (10.4)202270 (4.9)2213 (4.8)0?Potassium-sparing diuretic1877 (3.1)6000 (3.8)41251 (2.7)1230 (2.7)0 Open in a separate window SI conversion factors: to convert serum creatinine from mg/dL to mol/L, multiply by 88.4; to Exatecan Mesylate convert serum potassium from mEq/L to mmol/L, multiply.

Posted in p38 MAPK

Permalink

Comments are closed.

Categories